Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation.
about
Role of HMG-CoA Reductase Inhibitors in Neurological DisordersStatins for primary prevention of venous thromboembolismStatins for primary prevention of venous thromboembolismStatins for prevention of venous thromboembolismAnticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current RationaleModels for thrombin generation and risk of diseaseAspirin resistanceMore on: aspirin resistancePlatelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirinStatins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery diseaseOngoing clinical trials of the pleiotropic effects of statinsReinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromesStatins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trialCan we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility.Atorvastatin at reperfusion reduces myocardial infarct size in mice by activating eNOS in bone marrow-derived cells.Taking the thrombin "fork".Statin use and calcific uremic arteriolopathy: a matched case-control study.Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation.Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic strokeFactor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.The use of statins in acute coronary syndromes: the mechanisms behind the outcomes.Early use of statins in acute coronary syndromes.Early statin therapy for acute coronary syndromes.Why might statins prevent venous thromboembolism: what needs to be done to know more?Understanding the potential role of statins in pneumonia and sepsis.Blood coagulation dynamics in haemostasis.Statin use following intracerebral hemorrhage: a decision analysis.What is all that thrombin for?Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnosticsIs lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control studyDoes the genotype predict the phenotype? Evaluations of the hemostatic proteome.Association of statin use with risk and outcome of acute kidney injury in community-acquired pneumonia.Is there value in kinetic modeling of thrombin generation? Yes.Frequency and predictors of symptomatic intracranial hemorrhage after intravenous thrombolysis for acute ischemic stroke in a Brazilian public hospital.How aggressive should lipid lowering be among patients with acute coronary syndromes?Antiphospholipid syndrome and tissue factor: a thrombotic couple.Review article: The role of statins in reducing perioperative cardiac risk: Physiologic and clinical perspectives.Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management.Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome.Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.
P2860
Q22241432-E3BCA0F4-5CC0-4755-85A6-0CA001A51BACQ24187238-D828791D-C184-4C65-A97C-B20B024F5B31Q24204040-57B82C6E-7EEB-401C-B764-EDB90234F63BQ24241510-E0F197C2-E671-4E38-87AC-91738242F527Q26776077-9D22F6D0-296D-4417-970B-B4339BB46683Q27013171-0DDBFBB5-030B-4637-8B33-C260BFC82780Q28187611-4FD462FB-D78C-42F1-84B9-66C710FF87FEQ28210563-932835B9-8167-41A1-BDBF-9F8C75A752A1Q28217638-9981FC0D-1FA7-4098-A044-C72F7E140815Q28217889-188A5BBF-461F-4886-86AA-075864B1B38CQ28219321-B193D99A-E6EC-446B-97D4-50CCC5C1A0DFQ28219559-0CDFAE36-5844-4A17-9598-50696B1D66ACQ28481709-CFAABB7F-6142-4BAA-B2FC-73473D3E5F0EQ30243926-8BDCB416-6F57-4E92-BC87-AC7322B72372Q30301174-10ADB95B-B8EF-4367-828B-E4CAEFD00C02Q33924617-5BB18A56-EC90-42FE-8D4D-526F154FBEB1Q33948081-9C757A2E-7168-46C3-8C4B-AC55C6A107E1Q33951689-97179902-8CF1-4934-938B-DD254A20976DQ34095488-8B340314-FCAC-4460-8ACB-869C59520EE1Q34195043-958E5ACC-D961-46EA-A3EA-1D8D3BDB0F53Q34327214-FFA8D5F1-EE6C-419D-83CD-AF2A5D987339Q34674169-3A33850A-33C8-4E59-A9AE-46E4AA5B3D6BQ34979669-40AEE7DB-3209-4B81-9AEE-32AE7C8F0E73Q35001052-C238204E-E488-4FA5-8DC6-321460765DC2Q35116076-FBD042D6-E09E-4233-A677-3E1B0BA68910Q35154489-D2C65B41-88CC-43D8-92DA-B364C9C38E30Q35170660-F26F182A-D2A5-4F6E-AD39-2515F2778B22Q35181626-A58A9C0B-DE7F-4BD4-A030-6A82ED8A34B3Q35189544-F0BB22E7-46A9-4D67-8634-02864953053FQ35624965-FDFDC825-EDE4-4E63-9DD0-E354A39C31F6Q35904936-A3835191-4C68-4169-8465-91BCC55EB92DQ35995022-2AB1D469-6C3D-4A9F-9126-8EB69AB4216BQ36008892-3E5364C1-1620-45D9-87EE-64A07689C324Q36104057-5D6AC3F7-1394-4909-8FFF-7B27C589816DQ36178921-9171FF3F-46F8-44E9-8EFD-AD094064173EQ36458154-A907EBDC-C2A4-49F6-8EE0-EBB0EA051D80Q36641901-32B1265B-84F6-44AA-A97B-122504106009Q36754218-66CD0236-3487-4E56-A057-1620C8F39E38Q36807512-DF92A060-B02E-42E1-ABAE-1CFB72A68149Q36876792-8F6F02B1-C731-4410-8E56-A8C390C78928
P2860
Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Simvastatin depresses blood cl ...... ancing factor Va inactivation.
@en
Simvastatin depresses blood cl ...... ancing factor Va inactivation.
@nl
type
label
Simvastatin depresses blood cl ...... ancing factor Va inactivation.
@en
Simvastatin depresses blood cl ...... ancing factor Va inactivation.
@nl
prefLabel
Simvastatin depresses blood cl ...... ancing factor Va inactivation.
@en
Simvastatin depresses blood cl ...... ancing factor Va inactivation.
@nl
P2093
P1433
P1476
Simvastatin depresses blood cl ...... ancing factor Va inactivation.
@en
P2093
P304
P356
10.1161/01.CIR.103.18.2248
P407
P577
2001-05-01T00:00:00Z